Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ganaplacide - Novartis

Drug Profile

Ganaplacide - Novartis

Alternative Names: Ganaplacide; GNF-156; KAF-156

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antimalarials; Imidazoles; Piperazines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Vivax malaria

Most Recent Events

  • 16 Sep 2020 Novartis plans a phase II trial for Falciparum malaria (Combination therapy, In Infants, In Children) (PO, Tablet) in October 2020 (NCT04546633)
  • 22 Jul 2020 Novartis announces intention to submit regulatory applications for Malaria in or after 2024
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Falciparum-malaria in USA (PO, Tablet)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top